These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

105 related items for PubMed ID: 16817567

  • 1. Macugen treatment for wet age-related macular degeneration.
    Tobin KA.
    Insight; 2006; 31(1):11-4. PubMed ID: 16817567
    [Abstract] [Full Text] [Related]

  • 2. Pegaptanib sodium for the treatment of neovascular age-related macular degeneration: a review.
    Kourlas H, Schiller DS.
    Clin Ther; 2006 Jan; 28(1):36-44. PubMed ID: 16490578
    [Abstract] [Full Text] [Related]

  • 3. Regulatory aspects of drug approval for macular degeneration.
    Gryziewicz L.
    Adv Drug Deliv Rev; 2005 Dec 13; 57(14):2092-8. PubMed ID: 16316706
    [Abstract] [Full Text] [Related]

  • 4. Pegaptanib sodium for neovascular age-related macular degeneration: two-year safety results of the two prospective, multicenter, controlled clinical trials.
    VEGF Inhibition Study in Ocular Neovascularization (V.I.S.I.O.N.) Clinical Trial GroupDepartment of Ophthalmology, Harvard Medical School, Retina Service, Massachusetts Eye and Ear Infirmary, 243 Charles Street, Boston, MA 02114, USA. djdamico@meei.harvard.edu, D'Amico DJ, Masonson HN, Patel M, Adamis AP, Cunningham ET, Guyer DR, Katz B.
    Ophthalmology; 2006 Jun 13; 113(6):992-1001.e6. PubMed ID: 16647134
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Pegaptanib (Macugen): treating neovascular age-related macular degeneration and current role in clinical practice.
    Vavvas D, D'Amico DJ.
    Ophthalmol Clin North Am; 2006 Sep 13; 19(3):353-60. PubMed ID: 16935210
    [Abstract] [Full Text] [Related]

  • 8. Progression of choroidal neovascularization following injection of pegaptanib sodium (macugen) in two eyes with neovascular age-related macular degeneration.
    Williams AJ, Fekrat S.
    Am J Ophthalmol; 2006 Oct 13; 142(4):683-4. PubMed ID: 17011868
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. [Clinical experience in the treatment of neovascular age-related macular degeneration with pegaptanib].
    Maier M, Feucht N, Huebner M, Lohmann C.
    Klin Monbl Augenheilkd; 2008 Jun 13; 225(6):582-7. PubMed ID: 18516780
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Intraocular pressure effects of pegaptanib (Macugen) injections in patients with and without glaucoma.
    Frenkel RE, Mani L, Toler AR, Frenkel MP.
    Am J Ophthalmol; 2007 Jun 13; 143(6):1034-5. PubMed ID: 17524771
    [Abstract] [Full Text] [Related]

  • 13. RPE tears after pegaptanib treatment in age-related macular degeneration.
    Chang LK, Flaxel CJ, Lauer AK, Sarraf D.
    Retina; 2007 Sep 13; 27(7):857-63. PubMed ID: 17891009
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Pegaptanib for the treatment of age-related macular degeneration.
    Zhou B, Wang B.
    Exp Eye Res; 2006 Sep 13; 83(3):615-9. PubMed ID: 16678158
    [Abstract] [Full Text] [Related]

  • 18. Pegaptanib for neovascular age-related macular degeneration.
    Gragoudas ES, Adamis AP, Cunningham ET, Feinsod M, Guyer DR, VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group.
    N Engl J Med; 2004 Dec 30; 351(27):2805-16. PubMed ID: 15625332
    [Abstract] [Full Text] [Related]

  • 19. Short-term intraocular pressure trends following intravitreal pegaptanib (Macugen) injection.
    Hariprasad SM, Shah GK, Blinder KJ.
    Am J Ophthalmol; 2006 Jan 30; 141(1):200-1. PubMed ID: 16387003
    [Abstract] [Full Text] [Related]

  • 20. [Treatment of neovascular age-related macular degeneration with intravitreal vascular endothelial growth factor inhibitor--secondary publication].
    Larsen M, Sander B, Villumsen JE, Haamann PH, la Cour M, Lund-Andersen H, VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group.
    Ugeskr Laeger; 2005 Aug 29; 167(35):3301-5. PubMed ID: 16138974
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.